PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics

Reuters

05/14

PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in <a href="https://laohu8.com/S/TCRT">Alaunos Therapeutics</a>

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535302543"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535302543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535302543?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535302543","market":"us","top_or_hot":-1,"title":"PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in <a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PMGC Capital LLC, a subsidiary of <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in <a href=\"https://laohu8.com/S/TCRT\">Alaunos Therapeutics</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PMGC Capital LLC, a subsidiary of <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL3Z3jdl:1","article_id":"2535302543","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535302543","pubTimestamp":1747224057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. , has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. . This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4183":"个人用品","ELAB":"PMGC Holdings","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","TCRT":"Alaunos Therapeutics","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC"},"translate_title":"PMGC Capital LLC将提交附表13D，收购Alaunos Therapeutics 5.09%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAB":0.9,"NDAQ":0.9,"TCRT":0.9},"content_text":"PMGC Capital LLC to File Schedule 13D, Acquires 5.09% Stake in Alaunos Therapeutics\n\n\n        PMGC Capital LLC, a subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), has announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission, revealing its acquisition of a 5.09% stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT). This acquisition involves 83,500 shares of Alaunos Therapeutics, a clinical-stage oncology-focused cell therapy company based in Houston, Texas. PMGC Capital believes Alaunos is undervalued and sees significant potential for enhancing shareholder value. The firm aims to collaborate with Alaunos' leadership to explore strategic opportunities, including potential mergers, acquisitions, or partnerships, in areas such as financial technology and cryptocurrency. PMGC Capital commends Alaunos for its financially prudent management and clean capital structure amidst challenging market conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9451087-en) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}